[
  {
    "title": "Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients",
    "url": "https://ejhp.bmj.com/content/27/e1/e41",
    "authors": "Luis Margusino-Framiñán, Purificación Cid-Silva, Sandra Rotea-Salvo, Álvaro Mena-de-Cea, Francisco Suárez-López, Pilar Vázquez-Rodríguez, Manuel Delgado-Blanco, Ana Isabel Sanclaudio-Luhia, Isabel Martín-Herranz, Ángeles Castro-Iglesias",
    "institution": "Pharmacy Service, Universitary Hospital of A Coruña, A Coruña, Spain. Division of Clinical Virology, Biomedical Research Institute of A Coruña (INIBIC), Universitary Hospital of A Coruña (CHUAC), Sergas, University of A Coruña (UDC), A Coruña, Spain. Infectious Diseases Unit. Internal Medicine Service, Universitary Hospital of A Coruña (CHUAC), A Coruña, Spain. Hepatology Unit, Digestive System Service, University Hospital of A Coruña (CHUAC), A Coruña, Spain. Information Systems Department, University Hospital of A Coruña, A Coruña, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002060",
    "filters": {
      "actSubs": ["Sofosbuvir / Velpatasvir", "Ribavirin", "Glecaprevir / Pibrentasvir"],
      "indication": ["Hepatitis C Genotype 3", "Liver Fibrosis"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": ["Fisher’s Exact Test", "Mann-Whitney U Test", "Real-Time Polymerase Chain Reaction"],
      "studyLength": ["1 year - 2 years"],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": ["compliance"],
      "orphan": []
    }
  },
  {
    "title": "Evaluation of the stability of vancomycin solutions at concentrations used in clinical services",
    "url": "https://ejhp.bmj.com/content/27/e1/e87",
    "authors": "Morgane Masse, Stéphanie Genay, Anthony Martin Mena, Natacha Carta, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "Univ. Lille, CHU Lille, ULR 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002076",
    "filters": {
      "actSubs": ["Vancomycin hydrochloride"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)", "Mann-Whitney U Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Long-term stability of ready-to-use norepinephrine solution at 0.2 and 0.5 mg/mL",
    "url": "https://ejhp.bmj.com/content/27/e1/e93",
    "authors": "Sixtine Gilliot, Morgane Masse, Stéphanie Genay, Damien Lannoy, Christine Barthélémy, Bertrand Décaudin, Pascal Odou",
    "institution": "EA 7365–GRITA–Groupe de Recherche sur les formes Injectables et les Technologies Associées, University of Lille, CHU Lille, F-59000 Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2019-002146",
    "filters": {
      "actSubs": ["Norepinephrine"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography Fast Reversed-Phase", "Cochran Test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Cost efficacy analysis of abiraterone in newly diagnosed high risk metastatic castration sensitive prostate cancer",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.1",
    "authors": "A Soares, A Alcobia",
    "institution": "Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.8",
    "filters": {
      "actSubs": ["Abiraterone"],
      "indication": ["Prostate Cancer (Metastatic Castration Sensitive)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Application of a time slot model in oncology: delivery planning and process optimisation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A8.2",
    "authors": "C Bertino, M Di Gerardo, A Pirrone, E Dalla Fontana, G Caravella, A Spagnuolo, R Cursano",
    "institution": "Università Degli Studi Di Milano, Scienze Farmaceutiche-Scuola Di Specializzazione Farmacia Ospedaliera, Milano, Italy. Asst Melegnano Martesana, Farmacia, Vizzolo Predabissi, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.18",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": ["pharmacoeconomy"],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": ["institutional"],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Envisioning sustainability in personalised medicine: Fondo AIFA 5% and the Italian example",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A7.2",
    "authors": "F Bocchio, M Tizzoni, M Calvi, A Di Benedetto",
    "institution": "Fondazione Irccs Policlinico San Matteo Pavia, Uoc Farmacia, Pavia, Italy. Universita’ Degli Studi Di Milano, Scuola Di Specializzazione in Farmacia Ospedaliera, Pavia, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.16",
    "filters": {
      "actSubs": ["Venetoclax", "Eltrombopag", "Pembrolizumab", "Ruxolitinib", "Blinatumomab", "Trabectedina", "Cenegermin"],
      "indication": ["Leukaemia (Acute Myeloid)", "Lymphoma (Mantle Cell)", "Pure Red Cell Aplasia", "Lymphoma (Hodgkin)", "Lymphoma (non-Hodgkin)", "Myeloproliferative Neoplasm (BCR/JAK2-Rearranged)", "Leukaemia (Acute Lymphoblastic)", "Graft Versus Host Disease", "Ovarian Carcinoma", "Ovarian Serous Adenocarcinoma", "Neurotrophic Keratitis"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": ["10 - 50"],
      "criteriaMethod": [],
      "studyLength": ["1 year - 2 years"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": ["personalized"],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": ["multidisciplinary"],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Smartphone applications for patients diagnosed with genitourinary tumours: analysis of the quality using the mobile application rating scale",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A6.1",
    "authors": "MÁ Amor, R Collado-Borrell, V Escudero-Vilaplana, A Ribed-Sánchez, A Melgarejo-Ortuño, FJ García-Moreno, S García-Sánchez, Á Narrillos-Moraza, P Ruiz-Briones, A Herranz-Alonso, M Sanjurjo-Sáez",
    "institution": "Servicio De Farmacia, Hospital General Universitario Gregorio Marañón, Madrid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.13",
    "filters": {
      "actSubs": [],
      "indication": ["Genitourinary Cancers", "Prostate Cancer", "Cervical Cancer", "Testicular Cancer", "Ovarian Carcinoma"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": [],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Mobile Application Rating Scale (MARS)"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": ["mobileVR"],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Biological drugs for the treatment of moderate and severe plaque psoriasis: a cost analysis and an application of a correlation analysis to investigate cost effectiveness",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A1.2",
    "authors": "N Sagaria, D Mengato, I Corbucci, G Felluga, G Morandell, A Tavella",
    "institution": "School of Hospital Pharmacy, Department of Pharmaceutical Sciences University of Padova, Padova, Italy. Bolzano General Hospital, Hospital Pharmacy Department, Bolzano, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.2",
    "filters": {
      "actSubs": ["Adalimumab", "Infliximab", "Guselkumab"],
      "indication": ["Psoriasis (Moderate to Severe Plaque)"],
      "statedClass": ["Biosimilars"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Psoriasis Area and Severity Index (PASI)", "Correlation Analysis"],
      "studyLength": ["3 months - 5 months"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Economic comparison of therapeutic alternatives for firstline treatment of multiple myeloma",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.2",
    "authors": "MD Gil-Sierra, S Fenix-Caballero, MDP Briceño-Casado, M Dominguez-Cantero, EJ Alegre-Del Rey",
    "institution": "Hospital Universitario De Puerto Real, Pharmacy, Puerto Real, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.4",
    "filters": {
      "actSubs": ["Daratumumab", "Lenalidomide", "Bortezomib", "Thalidomide", "Melphalan", "Prednisone", "Dexamethasone"],
      "indication": ["Multiple Myeloma (Newly Diagnosed)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Systematic Review"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "ABC-VEN crosstab analysis: a decision making system for anticancer medicines",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.3",
    "authors": "M Fragiadaki, E Rinaki, M Petrongonas, L Tzimis",
    "institution": "Chania General Hospital, Pharmacy, 73300-Chania, Greece",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.5",
    "filters": {
      "actSubs": ["Daratumumab", "Trastuzumab emtansine", "Pantoprazole"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": ["Haematology", "Oncology", "Chemotherapy"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["ABC/Pareto Analysis"],
      "studyLength": ["5 months - 1 year"],
      "country": ["Greece"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Can rivaroxaban become cost saving compared with vitamin K antagonists in the treatment of patients with non-valvular atrial fibrillation in France?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A1.1",
    "authors": "S Robert, F Vincent, S Vengadessane",
    "institution": "Chru Nancy, Pharmacy, Vandoeuvre Les Nancy, France. Hospices Civils De Lyon, Pharmacie, Lyon, France. Université Paris Descartes, Faculté De Pharmacie De Paris, Paris, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.1",
    "filters": {
      "actSubs": ["Rivaroxaban"],
      "indication": ["Nonvalvular Atrial Fibrillation"],
      "statedClass": ["Vitamin K Antagonists", "Novel Oral Anticoagulants"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Cost effectiveness analysis of patient self-administration of medication during hospitalisation in a cardiology unit",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A6.2",
    "authors": "CA Sørensen, A De Thurah, M Lisby, C Olesen, SB Sørensen, U Enemark",
    "institution": "Hospital Pharmacy Central Denmark Region, Clinical Pharmacy-Randers Regional Hospital, Randers Nø, Denmark. Randers Regional Hospital, Medical Department-Cardiology Unit, Randers Nø, Denmark. Aarhus University, Clinical Medicine, Aarhus, Denmark. Aarhus University Hospital, Rheumatology, Aarhus, Denmark. Aarhus University Hospital, Research Centre of Emergency Medicine, Aarhus, Denmark. Hospital Pharmacy Central Denmark Region, Clinical Pharmacy-Aarhus University Hospital, Aarhus, Denmark. Aarhus University, Public Health, Aarhus, Denmark",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.14",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": ["Cardiology"],
      "numPatients": ["101 - 500"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Denmark"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": ["selfMedication"],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": ["errors"],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Evaluation of bispectral index monitoring in general anaesthesia through a health technology assessment method: a possible introduction in clinical practice in an Italian hospital?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A7.1",
    "authors": "E Guido, ME Borghesi, A Saccardi",
    "institution": "University of Milan, Specialisation School in Hospital Pharmacy, Milan, Italy. Asst Carlo Poma-Mantova, Hospital Pharmacy, Mantova, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.15",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Systematic Review"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": ["preopMedication"],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "National reporting system for drug shortages: classification and trends in reported causes from 2015 to 2018",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A5.2",
    "authors": "A Benhabib, P Maison",
    "institution": "French National Agency for Medicines and Health Products Safety, Health Products Survey, Saint-Denis, France. Strasbourg Faculty of Pharmacy, Hospital Pharmacy, Strasbourg, France. Ea 7379- Paris Est Creteil University Upec and Chic Hospital, Epidemiology Department, Créteil, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.12",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Study of the use of intravenous immunoglobulins during the fourth quarter of 2018 and analysis of its off-label use",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A2.1",
    "authors": "S Izquierdo Muñoz, A Pariente Junquera, A De Frutos Soto",
    "institution": "Hospital Clínico Universitario De Valladolid, Farmacia Hospitalaria, Valladolid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.3",
    "filters": {
      "actSubs": [],
      "indication": ["Demyelinating Neuropathies", "Myasthenia Gravis", "Myopathy", "Encephalitis", "Encephalomyelitis", "Morvan Syndrome", "Paraneoplastic Syndrome", "Refractory Atopic Dermatitis", "Paraneoplastic Dermatomyositis", "Scleroderma", "Antisynthetase Syndrome"],
      "statedClass": ["Intravenous Immunoglobulins (IVIg)"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": ["offLabel"],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Effectiveness evaluation of high cost drugs for advanced non-small-cell lung cancer: real world evidence, compliance with clinical practice guidelines and economic evaluation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A3.1",
    "authors": "A Isoardo, E Grande, MM Ferrero, C Fruttero",
    "institution": "Ao S Croce E Carle, SC Farmacia Ospedaliera, Cuneo, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.6",
    "filters": {
      "actSubs": ["Pemetrexed", "Erlotinib", "Gefitinib", "Afatinib", "Osimertinib", "Crizotinib", "Pembrolizumab", "Nivolumab"],
      "indication": ["Advanced Non-Small Cell Lung Cancer"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": ["Kaplan-Meier Method"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": ["compliance"],
      "orphan": []
    }
  },
  {
    "title": "New cancer drug approvals in Portugal",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A3.2",
    "authors": "A Alcobia, A Soares",
    "institution": "Hospital Garcia De Orta, Pharmacy Department, Almada, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.7",
    "filters": {
      "actSubs": ["Midostaurin", "Olaparib", "Brentuksimab vedotin", "Vedotin", "Pomalidomide", "Durvalumab", "Venetoclax", "Ixazomib", "Alectinib", "Atezolizumab", "Cabozantinib"],
      "indication": ["Refractory Cancer", "Metastatic Cancer"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Budget impact analysis of a natalizumab extended interval dosing regimen",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.2",
    "authors": "E Pierobon, A Mastrogiacomo, F Capano, D Ielo",
    "institution": "AOU San Luigi Gonzaga, Pharmacy, Turin, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.9",
    "filters": {
      "actSubs": ["Natalizumab"],
      "indication": ["Progressive Multifocal Leukoencephalopathy", "Multiple Sclerosis"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["501 - 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Introduction of rituximab biosimilar: an opportunity to improve health system efficiency?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A4.3",
    "authors": "C Panciroli, L Cervi, D Mazza, G Mangoni, M Dall’aglio, F Ruggiero, ML Medaglia",
    "institution": "Asst Grande Ospedale Metropolitano Niguarda, SC Farmacia, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.10",
    "filters": {
      "actSubs": ["Rituximab"],
      "indication": [],
      "statedClass": ["Biosimilars"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["More than 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": ["vigilance"],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": ["adverseEvents"],
      "adherence": ["adherence"],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Assessment of asthma diagnosed population eligible for new monoclonal antibody therapy and related cost in the Veneto region",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A5.1",
    "authors": "L Degli Esposti, V Perrone, D Sangiorgi, AM Menti, M Andretta",
    "institution": "Clicon SRL-Health-Economics and Outcomes Research, Clicon SRL-Health-Economics and Outcomes Research, Ravenna, Italy. Uoc Hta-Azienda Zero-Regione Veneto, Uoc Hta-Azienda Zero-Regione Veneto, Padova, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.11",
    "filters": {
      "actSubs": ["Theophylline"],
      "indication": ["Asthma (Severe Refractory)"],
      "statedClass": ["Monoclonal Antibodies", "Inhaled Corticosteroids", "Long-Acting β Adrenoceptor Agonists", "Antileukotriene Agents", "Anticholinergics", "Systemic Corticosteroids"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["More than 1000"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Impact of supply problems in a hospital pharmacy service",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A8.1",
    "authors": "B Zarate, Á Pieras López, R Menárguez Blanc, A Iglesias Carbajo, C Álvarez Asteinza, A Lozano Blazquez, Á Arias-Martinez, I Maray Mateos, MD Macía Rivas, CL Fernández Laguna",
    "institution": "Hospital Universitario Central De Asturias, Pharmacy, Oviedo, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.17",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["3 months - 5 months"],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Hospital pharmacists aged <45 years: an employment status and job satisfaction survey in Italy",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A9.1",
    "authors": "SE Campbell Davies, G Bagaglini, F Brera",
    "institution": "Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, Milano, Italy. Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, Roma, Italy. Italian Society of Hospital Pharmacy Sifo, Young Pharmacists, San Donà Di Piave, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.19",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["Less than 3 months"],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": ["youngPharma"],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Implementation of home delivery and telepharmacy systems in a third level hospital",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A9.2",
    "authors": "J Cordero-Ramos, Ú Baños-Roldán, JA Fernandez-González-Caballos, C Castillo-Martin, EM Delgado-Cuesta",
    "institution": "Hospital Universitario Virgen Macarena, Hospital Pharmacy, Seville, Spain. Hospital Universitario Virgen Macarena, Primary Care Pharmacy Department, Seville, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.20",
    "filters": {
      "actSubs": [],
      "indication": ["Multiple Sclerosis"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": ["Outpatient Clinic"],
      "numPatients": ["101 - 500"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": ["telepharmacy"],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": ["adverseEvents"],
      "adherence": ["adherence"],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": ["delivery"]
    }
  },
  {
    "title": "Improvement in an antimicrobial stewardship programme after implementing a screening alert system",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A10.1",
    "authors": "E Tevar, MJ Castillo Méndez, A Ferrer Machín, ML Padilla Salazar, L Abella Vázquez, J Ode Febles, K Álvarez Tosco, M Hayek Peraza, MÁ Ocaña Gómez, J Merino Alonso",
    "institution": "Hospital Nuestra Señora De La Candelaria, Pharmacy Service, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Computer Department, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Internal Medicine, Santa Cruz De Tenerife, Spain. Hospital Nuestra Señora De La Candelaria, Microbiology Service, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.21",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Quasi-Experimental Design"],
      "setting": ["Hospital"],
      "ward": ["Cardiology", "Vascular Surgery", "General Surgery", "Geriatrics", "Internal Medicine", "Neurology", "Traumatology"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": ["softwareAided"],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": ["stewardship"],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Economic impact of the introduction of lamivudine plus dolutegravir bitherapy in HIV naive patients",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A10.2",
    "authors": "L Cantarelli, J Gonzalez Garcia, B Del Rosario Garcia, J Ramos Rodriguez, F Gutierrez Nicolas, J Garcia Cairos, S Garcia Gil, GJ Nazco Casariego",
    "institution": "Complejo Hospitalario Universitario De Canarias, Pharmacy, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.22",
    "filters": {
      "actSubs": ["Dolutegravir", "Abacavir", "Lamivudine", "Emtricitabine", "Tenofovir", "Raltegravir"],
      "indication": ["HIV (Treatment-Naive)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Efficiency of precision dosing with intravenous immunoglobulins in patients with haematological malignancies",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A11.1",
    "authors": "M Dominguez Cantero, FJ Salmeron-Navas, EM Barreiro-Fernandez, C Moreno-Ramos, MP Briceño-Casado",
    "institution": "Hospital Universitario Puerto Real, Servicio De Farmacia, Cadiz, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.23",
    "filters": {
      "actSubs": ["Intravenous Immunoglobulin (IVIg)"],
      "indication": ["Hematologic Malignancy", "Immunodeficiency", "Autoimmune Hemolytic Anemia", "Idiopathic Thrombocytopenic Purpura"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Economic analysis of osimertinib in previously untreated EGFR mutant advanced non-small cell lung cancer",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A11.2",
    "authors": "A Ferrer Machín, LG José Arístides, JA Martín Conde, T Betancor García, M Vera Cabrera, S Hernández Rojas, I González García, K Álvarez Tosco, J Merino Alonso",
    "institution": "Hospital Pharmacist, Pharmacy Service, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.24",
    "filters": {
      "actSubs": ["Osimertinib", "Afatinib", "Gefitinib", "Erlotinib"],
      "indication": ["Advanced Non-Small Cell Lung Cancer (EGFR-Mutated)"],
      "statedClass": ["Tyrosine Kinase Inhibitors"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Assessment of regorafenib, ramucirumab and cabozantinib as secondline therapy in hepatocarcinoma and alfa-fetoprotein value ≥400 ng/mL",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A12.1",
    "authors": "M Camean-Castillo, S Fenix-Caballero, FJ Salmeron-Navas, M Dominguez-Cantero, JM Borrero-Rubio",
    "institution": "Hospital Universitario Puerto Real, Pharmacy, Puerto Real, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.25",
    "filters": {
      "actSubs": ["Regorafenib", "Ramucirumab", "Cabozantinib", "Sorafenib"],
      "indication": ["Hepatocarcinoma"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Meta-Analysis"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Bucher's Method", "Shakespeare Method"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Out of supply of chemotherapy injectable medicines over 9 months: patient impact",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A12.2",
    "authors": "F Charbonneau, Y Brasleret, MA Zilavec, C Naine, J Grimaux, G Svrcek",
    "institution": "Soissons Hospital Centre, Pharmacy Unit, Soissons, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.26",
    "filters": {
      "actSubs": ["Bleomycin", "Mitomycin C", "Docetaxel"],
      "indication": ["Ovarian Carcinoma", "Bladder Cancer", "Squamous Cell Carcinoma of the Rectum", "Prostate Cancer"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": ["patientIntervention"],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Impact of French experiment for incentivising etanercept biosimilar use after 10 months",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A12.3",
    "authors": "P Paubel, A Degrassat-Théas, F Bocquet",
    "institution": "Faculté De Pharmacie De Paris, Institut Droit Et Santé- Inserm Umr S 1145, Paris, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.27",
    "filters": {
      "actSubs": ["Etanercept"],
      "indication": [],
      "statedClass": ["Biosimilars"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital", "Community Pharmacy"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Cost minimisation study of the biological treatment of inflammatory bowel disease: ustekinumab versus vedolizumab",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A13.1",
    "authors": "L Cantarelli, F Gutierrez Nicolas, B Del Rosario Garcia, J Ramos Rodriguez, J Garcia Cairos, JA Morales Barrios, S Garcia Gil, GA Gonzalez De La Fuente, J Gonzalez Garcia, GJ Nazco Casariego",
    "institution": "Complejo Hospitalario Universitario De Canarias, Pharmacy, Santa Cruz De Tenerife, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.28",
    "filters": {
      "actSubs": ["Ustekinumab", "Vedolizumab"],
      "indication": ["Inflammatory Bowel Disease"],
      "statedClass": ["Tumor Necrosis Factor Alpha (TNF-α) Inhibitors"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": ["pharmacoeconomy"],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Economic impact of switching the administration route of tocilizumab in polyarticular juvenile idiopathic arthritis",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A13.2",
    "authors": "M Rodriguez Reyes, F Bossacoma Busquets, M Sanchez Celma, J Arrojo Suarez, A Comes Escoda, C Latre Gorbe, E Iglesias Jimenez, J Anton Lopez",
    "institution": "Hospital Clinic Barcelona, Pharmacy, Barcelona, Spain. Hospital Sant Joan De Déu/Fundació Salut Empordà, Pharmacy, Esplugues De Llobregat, Spain. Hospital Sant Joan De Déu, Pharmacy, Esplugues De Llobregat, Spain. Hospital Sant Joan De Déu, Paediatrics, Esplugues De Llobregat, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.29",
    "filters": {
      "actSubs": ["Tocilizumab"],
      "indication": ["Polyarticular Juvenile Idiopathic Arthritis"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cross-Sectional Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": ["pediatrics"],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": ["adherence"],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Trans-interface gain share programme for biosimilar infliximab",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A14.1",
    "authors": "C Mc Gann, S Cullen, B Love, J Carr",
    "institution": "Connolly Hospital, Pharmacy Department, Blanchardstown, Ireland",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.30",
    "filters": {
      "actSubs": ["Infliximab", "Vedolizumab"],
      "indication": [],
      "statedClass": ["Biosimilars"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": ["Rheumatology", "Gastroenterology"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["5 months - 1 year"],
      "country": ["Ireland"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Cost minimisation study in severe asthma treatment",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A14.2",
    "authors": "J Ramos Rodríguez, S García Gil, L Cantarelli, J González García, C Romero Delgado, J García Cairós, G Calzado Gómez, GA González De La Fuente, B Del Rosario García, GJ Nazco Casariego, F Gutiérrez Nicolás",
    "institution": "Hospital Universitario De Canarias, Pharmacy, San Cristóbal De La Laguna, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.31",
    "filters": {
      "actSubs": ["Omalizumab"],
      "indication": ["Severe Asthma (IgE-Mediated)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": ["Pneumology"],
      "numPatients": ["51 - 100"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": ["multidisciplinary"],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Application of the ABC analysis method for optimising the stock management of medical devices in common use",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A15.1",
    "authors": "M Belhouari, N Nchinech, H Attjioui, N Bouhlala, B Elouadghiri, J Lamsaouri",
    "institution": "Mohammed V Military Training Hospital, Pharmacy, Rabat, Morocco. Mohammed V University-Faculty of Medicine and Pharmacy of Rabat, Chis, Rabat, Morocco",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.32",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Universal Kits", "Sterile Gloves", "Infusers", "Plaster Strips", "Guedel Cannulas", "Y Fittings"],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["ABC/Pareto Analysis"],
      "studyLength": [],
      "country": ["Morocco"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": ["medicalDevices"],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Evaluating the methodological quality of pivotal clinical trial publications for orphan drugs authorised in 2018. Are they reliable?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A15.2",
    "authors": "R Iglesias Gómez, F Luna, J Moya Sola, M Tordera Baviera, MJ Company Albir, T Palanques Pastor, I Beltran Garcia, JL Poveda Andres",
    "institution": "Hospital Universitario Y Politécnico La Fe De Valencia, Servicio De Farmacia, Valencia, Spain. Hospital General De Agudos Carlos G. Durand, Servicio De Farmacia, Buenos Aires, Argentina",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.33",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain", "Argentina"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": ["orphan"]
    }
  },
  {
    "title": "Cost of stockout. A growing problem",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A16.1",
    "authors": "G Rodriguez Torne, MJ Sanchez Cuenca, F Burgos Sierra, C Fernandez Oropesa",
    "institution": "Hospital De Baza, Pharmacy Service, Granada, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.34",
    "filters": {
      "actSubs": ["Piperacillin / Tazobactam", "Docetaxel", "Paclitaxel", "Levothyroxine (IV)"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": []
    }
  },
  {
    "title": "Future distribution models for paid pharmaceuticals: the patient’s perspective",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A16.2",
    "authors": "C Olesen, MN Pedersen, MS Wellner",
    "institution": "Hospital Pharmacy Central Denmark Region, Clinical Pharmacy-Aarhus, Aarhus C, Denmark. Hospital Pharmacy Central Denmark Region, Department of for Paid Pharmaceuticals, Aarhus C, Denmark",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.35",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["101 - 500"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Denmark"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": ["patientIntervention"],
      "nursesReccomend": [],
      "telepharmacy": ["telepharmacy"],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": ["delivery"]
    }
  },
  {
    "title": "Impact of the implementation of the falsified medicines directive at the Lisbon Portuguese Institute of Oncology (FG, EPE)",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A16.3",
    "authors": "AC Franco, A Gouveia",
    "institution": "Lisbon Portuguese Institute of Oncology Francisco Gentil Epe, Hospitalar Pharmacy, Lisbon, Portugal",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.36",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Portugal"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": ["falsified"]
    }
  },
  {
    "title": "Four year study of drugs shortages in two public hospitals",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A17.1",
    "authors": "A Decoene, S Traore, A Pruvost, I Walbecq, P Mazaud",
    "institution": "Ch De Dunkerque, Pharmacy, Dunkerque, France. Chu De Lille, Pharmacy, Lille, France. Ch De Valenciennes, Pharmacy, Valenciennes, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.37",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Student's T-test"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": ["institutional"],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Four years of shortages regarding the anatomic, therapeutic and chemical classification",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A17.2",
    "authors": "A Decoene, S Traore, I Walbecq, P Mazaud",
    "institution": "Ch De Dunkerque, Pharmacy, Dunkerque, France. Chu De Lille, Pharmacy, Lille, France",
    "DOI": "",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": ["Cephalosporins"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": ["resistance"],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Impact of medicine shortages on an outpatient clinic of a general hospital ",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A18.1",
    "authors": "I Puértolas Tena, M Comet Bernad, C Moncín Torres",
    "institution": "Hospital Royo Villanova, Servicio De Farmacia, Zaragoza, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.39",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": ["Outpatient Clinic"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": ["outpatient"],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Survey of drug shortages in Hungarian hospitals",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A18.2",
    "authors": "RG Vida, S Sebők, B Nyaka, J Hornyák, L Botz",
    "institution": "University of Pécs Faculty of Pharmacy, Department of Pharmaceutics and Central Clinical Pharmacy, Pécs, Hungary. Semmelweis University, University Pharmacy Department of Pharmacy Administration, Budapest, Hungary",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.40",
    "filters": {
      "actSubs": ["Digoxin", "Sodium Ferric Gluconate", "Phytomenadione", "Immunoglobulin", "Idarubicin", "Amoxicillin / Clavulanic acid"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Hungary"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": ["interview"],
      "selection": ["selection"],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Drug shortages and drug unavailability: analysis from an Italian hospital",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A19.1",
    "authors": "A Zovi, C Inserra, M Piacenza, V Stefania",
    "institution": "Asst Fatebenefratelli Sacco-L Sacco Hospital, Pharmacy, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.41",
    "filters": {
      "actSubs": ["Ampicillin", "Ceftazidime", "Midazolam", "Oxacillin", "Ferrous gluconate", "Glutathione", "Piperacillin / Tazobactam", "Lysine acetylsalicylate", "Hydrocortisone", "Suxamethonium", "Cefepime", "Methylprednisolone", "Heparin", "Atracurium", "Mupirocin", "Chlorphenamine", "Alprostadil", "Etilefrine", "Diazepam", "Lorazepam", "Fructose", "Labetalol", "Danazol", "Sodium nitroprusside"],
      "indication": [],
      "statedClass": ["Antibiotics", "Non-Steroidal Anti-Inflammatory Drugs", "Benzodiazepines", "Antihypertensives", "Dietetics", "Anaesthetics", "Urological Drugs", "Antihistamines", "Adrenergic Drugs"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "How much does falsified medicines directive actually costs? Detailed cost evaluation of serialisation in a representative sample of Hungarian hospital pharmacies",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A19.2",
    "authors": "A Fittler, K Richter, P Vajda, Z Bodrogi, RG Vida, R Bella, S Kovács, A Zemplényi, L Botz",
    "institution": "University of Pécs, Department of Pharmaceutics and Central Clinical Pharmacy, Pécs, Hungary. Szent Borbála Hospital, Department of Pharmacy, Tatabánya, Hungary. University of Pécs, Department of Pharmacoeconomics, Pécs, Hungary",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.42",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Hungary"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": ["interview"],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": ["falsified"]
    }
  },
  {
    "title": "Shortages of medicines in hospital: results of a survey on the perception of health workers in the wards VSV real world",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A20.1",
    "authors": "A Zovi, UM Musazzi, F Cilurzo, P Minghetti",
    "institution": "Asst Fatebenefratelli Sacco-L Sacco Hospital, Pharmacy, Milan, Italy. University of Milan, Department of Pharmaceutical Sciences, Milano, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.43",
    "filters": {
      "actSubs": ["Danazol", "Ceftazidime", "Oxacillin", "Lysine acetylsalicylate"],
      "indication": [],
      "statedClass": ["Antibiotics", "Corticosteroids", "Gastroprotectors", "Antihypertensives", "Benzodiazepines", "Psychostimulants", "Nutritional Agents", "Antihistamines", "Blood Products", "Biologicals"],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": ["interview"],
      "selection": ["selection"],
      "stock": ["stock"],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Application of hazard vulnerability analysis to evaluate the risk level of medicine shortages",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A20.2",
    "authors": "E Di Martino, D Vinci Leonardi, R Giammona, A Provenzani, P Polidori",
    "institution": "Università Degli Studi Di Palermo, Stebicef, Palermo, Italy. Università Degli Studi Di Messina, Chimica-Biologia-Farmacia-Scienze Ambientali, Messina, Italy. Irccs Ismett, Clinical Pharmacy, Palermo, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.44",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Hazard Vulnerability Analysis"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Management of drug shortages",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A20.3",
    "authors": "MI Bernias Domínguez, M Mañes Sevilla, B Martin Cruz, B Santiago Gallego, I Escribano Valenciano, C Moriel Sánchez",
    "institution": "Hospital Universitario De Móstoles, Hospital Pharmacy, Madrid, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.45",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": ["Antimetabolites", "Corticosteroids", "Antiarrhythmics", "Antipsychotics"],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": ["selection"],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Economic impact of drug shortages",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A21.1",
    "authors": "C Aparicio Carreño, Y Labeaga Beramendi, B Rodriguez, B Fernández González, A Gándara Ande, FJ Barbazán Vázquez, C Martínez-Múgica Barbosa, C Durán Román",
    "institution": "Cabueñes Hospital University, Pharmacy, Gijón, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.46",
    "filters": {
      "actSubs": ["Piperacillin / Tazobactam", "Alprostadil", "Dexchlorpheniramine", "Magnesium sulphate", "Clorazepate dipotassium", "Metoclopramide", "Sodium chloride", "Doxycycline", "Isoniazid / Pyrazinamide / Rifampicin", "BCG Vaccine (Tice strain)"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital", "Community Pharmacy"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": ["switching"],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Referencing a midline: how to make a choice?",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A21.2",
    "authors": "P Behague, M Debailleul, L Lampe, N Garnier, V Colas, M Raoult, F Cathelineau, N Guenault, V Leclercq, C Canevet, E Floret",
    "institution": "Hôpital Saint Philibert, Service Pharmacie, Lomme, France. Hôpital Saint Philibert, Equipe Opérationnelle D’hygiène, Lomme, France. Hôpital Saint Philibert, Service D’anesthésie, Lomme, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.47",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Midlines"],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": ["3 months - 5 months"],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": ["medicalDevices"],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": ["youngPharma"],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": []
    }
  },
  {
    "title": "Compatibility and stability assessment of a sodium glycerophosphate formulation mixed in bags for neonatal total parenteral nutrition",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A22.1",
    "authors": "A Isoardo, E Grande, MM Ferrero, M Viglione, B Rolando, R Fruttero, C Fruttero",
    "institution": "Ao S Croce E Carle, SC Farmacia Ospedaliera, Cuneo, Italy. Università Degli Studi Di Torino, Dipartimento Di Scienza E Tecnologia Del Farmaco, Torino, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.48",
    "filters": {
      "actSubs": ["Sodium glycerophosphate"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": ["neonatology"],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": ["nutrition"],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": ["incompatibilities"]
    }
  },
  {
    "title": "Microbiological stability test of 15% topical resorcinol for quality control",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A22.2",
    "authors": "J Cordero-Ramos, M Delgado-Valverde, V Merino-Bohórquez, C Castillo-Martin, FJ Falcón-Rodríguez, M Cameán-Fernández",
    "institution": "Hospital Universitario Virgen Macarena, Hospital Pharmacy, Seville, Spain. Hospital Universitario Virgen Macarena, Microbiology Department, Seville, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.49",
    "filters": {
      "actSubs": ["Resorcinol"],
      "indication": ["Hidradenitis suppurativa"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Terlipressin pH stability for continuous infusion",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A23.1",
    "authors": "A Castro Balado, J González-López, S Blanco-Dorado, EJ Bandín-Vilar, L García-Quintanilla, I Varela-Rey, M Busto Iglesias, M González-Barcia, I Zarra-Ferro",
    "institution": "Complejo Hospitalario Universitario De Santiago De Compostela, Hospital Pharmacist Service, Santiago De Compostela, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.50",
    "filters": {
      "actSubs": ["Terlipressin"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Physicochemical stability of cefepime in polypropylene syringes and in elastomeric devices",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A23.2",
    "authors": "E D’huart, H Zenier, J Vigneron, A Charmillon, B Demore",
    "institution": "University Hospital of Nancy, Pharmacy Department, Vandoeuvre Lès Nancy, France. University Hospital of Nancy, Infectious and Tropical Diseases Department, Vandoeuvre Lès Nancy, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.51",
    "filters": {
      "actSubs": ["Cefepime"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Polypropylene Syringes", "Elastomeric Devices"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Physicochemical stability of cefazolin in polypropylene syringes and in elastomeric devices",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A24.1",
    "authors": "E D’huart, N Sobalak, J Vigneron, A Charmillon, B Demore",
    "institution": "University Hospital of Nancy, Pharmacy Department, Vandoeuvre Lès Nancy, France. University Hospital of Nancy, Infectious and Tropical Diseases Department, Vandoeuvre Lès Nancy, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.52",
    "filters": {
      "actSubs": ["Cefazolin"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Polypropylene Syringes", "Elastomeric Devices"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Physicochemical stability of aztreonam in polypropylene syringes at high concentration for intensive care units",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A24.2",
    "authors": "YE Nisse, J Vigneron, F Blaise, E D’huart, A Charmillon, B Demoré",
    "institution": "Chru Nancy, Pharmacy, Vandoeuvre-Lès-Nancy, France. Chru Nancy, Infectious Diseases Department, Vandoeuvre-Lès-Nancy, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.53",
    "filters": {
      "actSubs": ["Aztreonam"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Polypropylene Syringes"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": ["Intensive Care"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Levofloxacin 0.05% eye drops: a case study",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A24.3",
    "authors": "M Martín Marqués, A De Dios López, J Del Estal Jiménez, PA López Broseta, MÁ Roch Ventura, A Sanjuan Belda, S Jornet Montaña, E Esteve Pitarch, M Vuelta Arce, M Mendoza Aguilera, L Canadell Vilarrasa",
    "institution": "Hospital Universitari Joan Xxiii, Pharmacy, Tarragona, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.54",
    "filters": {
      "actSubs": ["Levofloxacin"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case Reports / Series"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": ["neonatology"],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": ["shortages"],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Intravenous perfusion of ceftolozane–tazobactam using elastomeric infusion pumps",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A25.1",
    "authors": "S Rotea, M García, B Feal, C Fernández, V Giménez, I Martín",
    "institution": "Hospital Pharmacy, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.55",
    "filters": {
      "actSubs": ["Ceftolozane / Tazobactam"],
      "indication": ["Pneumonia (Hospital Acquired)", "Severe Abdominal Infection", "Severe Urinary Infection"],
      "statedClass": [],
      "typeOfMedical": ["Elastomeric Infusion Pumps"],
      "studyDesign": ["Case-Control (Retrospective) Study"],
      "setting": ["Hospital"],
      "ward": ["Home Care Unit"],
      "numPatients": ["Less than 10"],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": ["homeCare"],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": ["offLabel"],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Treatment of recurrent otomycosis with local application of a compounded formulation of voriconazole ear drops: case series",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A25.2",
    "authors": "L Carrasco Piernavieja, E Zhan Zhou, M Dominguez Bachiller, AM Martín De Rosales Cabrera, MS Marcos Salazar, M Perez Encinas",
    "institution": "Hospital Universitario Fundación Alcorcón, Hospital Pharmacy, Alcorcón, Spain. Hospital Universitario Fundación Alcorcón, Otorhinolaryngology, Alcorcón, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.56",
    "filters": {
      "actSubs": ["Voriconazole"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Case Reports / Series"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": ["10 - 50"],
      "numPrescriptions": [],
      "criteriaMethod": ["Statistical Package for the Social Sciences (SPSS)", "STATA", "McNemar Test"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": ["patientIntervention"],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": ["adverseEvents"],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Evaluation of the production accuracy and error rate in the automated compounding of cytotoxic preparations by a robot",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A26.1",
    "authors": "BR Kujau, J Raffaelli, C Klaas",
    "institution": "Universitätsklinikum Münster, Zentrale Einrichtung Apotheke, Münster, Germany. Loccioni Deutschland Gmbh, Humancare, Calw, Germany",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.57",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": ["More than 1000"],
      "criteriaMethod": [],
      "studyLength": ["5 months - 1 year"],
      "country": ["Germany"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": ["safetyProfile"],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": ["automated"],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Closed system transfer device based on air filtration: the drug vapour challenge",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A26.2",
    "authors": "G Levin",
    "institution": "Simplivia Healthcare, Research and Development, Hod Hasharon, Israel",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.58",
    "filters": {
      "actSubs": ["Cyclophosphamide", "Florourasil (5-FU)"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": ["Closed System Drug-Transfer Device (CSTD)", "Vial Adaptors"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Liquid Chromatography Tandem - Mass Spectrometry (LC–MS/MS)"],
      "studyLength": [],
      "country": ["Israel"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": ["riskSafety"],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Management of non-administered chemotherapy preparation: an opportunity to minimise drug waste in oncology pharmacy",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A27.1",
    "authors": "A El Assil, C Adade, R Issa, H Bechar, A Zedou, A Fassi Fihri, Y Rahali",
    "institution": "Mohamed V University-Faculty of Medecine and Pharmacy, Department of Pharmacy, Rabat, Morocco. National Institute of Oncology-Ibn Sina University Hospital, Department of Pharmacy, Rabat, Morocco",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.59",
    "filters": {
      "actSubs": ["Docetaxel"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Cohort (Prospective Observational Study)"],
      "setting": ["Hospital"],
      "ward": ["Centralised Cytotoxic Preparation Unit"],
      "numPatients": [],
      "numPrescriptions": ["51 - 100"],
      "criteriaMethod": [],
      "studyLength": ["5 months - 1 year"],
      "country": ["Morocco"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": ["prepareIV"],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": ["vigilance"],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": ["incompatibilities"]
    }
  },
  {
    "title": "Comparative biophysical stability study of ziv-aflibercept (Zaltrap, opened vials) stored at 4°C and room temperature for 2 weeks",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A27.2",
    "authors": "J Hermosilla Fernández, A Salmeron García, J Cabeza, N Navas",
    "institution": "Biomedical Research Institute Ibs Granada, Analytical Chemistry-Science Faculty-University of Granada, Granada, Spain. Biomedical Research Institute Ibs Granada, Clinical Pharmacy-San Cecilio University Hospital, Granada, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.60",
    "filters": {
      "actSubs": ["Ziv-Aflibercept"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Dynamic Light Scattering", "Size-Exclusion Chromatography (SEC)"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Use of cabazitaxel and reduction of waste: the potential of drug day",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A28.1",
    "authors": "L Gasperoni, M Nardelli, A Caraffa, A Colicchio, M Mancini",
    "institution": "Azienda Ospedaliera Ospedali Riuniti Marche Nord, Uoc Farmacia, Pesaro, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.61",
    "filters": {
      "actSubs": ["Cabazitaxel"],
      "indication": ["Prostate Cancer (Metastatic Castration Resistant)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Short term stability of diluted solutions of the monoclonal antibody daratumumab",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A28.2",
    "authors": "G Mangoni, F Selmin, L Camuffo, L Cancanelli, M Piccoli, M Rivano, L Cervi, F Cilurzo, P Minghetti",
    "institution": "Università Degli Studi Di Milano, School of Specialisation in Hospital Pharmacy, Milano, Italy. Università Degli Studi Di Milano, Department of Pharmaceutical Sciences, Milano, Italy. Asst Grande Ospedale Metropolitano Niguarda, SC Farmacia, Milano, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.62",
    "filters": {
      "actSubs": ["Daratumumab"],
      "indication": ["Multiple Myeloma"],
      "statedClass": [],
      "typeOfMedical": ["Low Density Polyethylene (LDPE) Bags"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Size Exclusion Chromatography - High Performance Liquid Chromatography (SEC-HPLC)", "Dynamic Light Scattering", "Nanoparticle Tracking Analysis (NTA)"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Stability of compounded nivolumab solution after pneumatic system transportation",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A29.1",
    "authors": "L Camuffo, F Selmin, F Vasile, M Rivano, M Piccoli, G Mangoni, L Cancanelli, M Fazio, F Cilurzo, P Minghetti",
    "institution": "University of Milan, School in Hospital Pharmacy, Milan, Italy. Humanitas Research Hospital, Pharmacy, Rozzano, Italy. University of Milan, Department of Pharmaceutical Sciences, Milan, Italy. San Raffaele Hospital, Pharmacy, Milan, Italy. University of Milan, Department of Chemistry, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.63",
    "filters": {
      "actSubs": ["Nivolumab"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Dynamic Light Scattering", "Nuclear Magnetic Resonance", "Size Exclusion Chromatography - High Performance Liquid Chromatography (SEC-HPLC)"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": ["automated"],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Increasing pharmacy productivity by expanding the role of the intravenous compounding robot in a comprehensive cancer centre",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A29.2",
    "authors": "M Capilli, M Federici, T Comandone, G Maffeis, F Foglio, L Omini, F Enrico",
    "institution": "University of Turin, Drug Science and Technology-School of Specialisation in Hospital Pharmacy, Turin, Italy. Loccioni, Angeli Di Rosora, Ancona, Italy. University of Turin, Drug Science and Technology, Turin, Italy. Fpo Irccs Candiolo, Hospital Pharmacy, Candiolo, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.64",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": ["prepareIV"],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": ["automated"],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": ["errors"],
      "administrative": ["administrative"],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Mitomycin C stability according to pH and temperature conditions",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A29.3",
    "authors": "G Miralles Andreu, I Truyols García, M Pomares Bernabeu, L Soriano Irigaray, L Peral Ballester, A Navarro Ruiz",
    "institution": "Hospital General Universitario De Elche, Hospital Pharmacy Department, Elche, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.65",
    "filters": {
      "actSubs": ["Mitomycin C"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)"],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "In use physicochemical and microbiological stability of diluted solutions of the monoclonal antibody nivolumab",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A30.1",
    "authors": "M Rivano, F Selmin, L Camuffo, L Cancanelli, G Mangoni, MA Piccoli, G Longobardo, F Cilurzo, P Minghetti",
    "institution": "University of Milan, School of Hospital Pharmacy, Milan, Italy. University of Milan, Department of Pharmaceutical Sciences, Milan, Italy. Irccs San Raffaele, Pharmacy, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.66",
    "filters": {
      "actSubs": ["Nivolumab"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Dynamic Light Scattering", "Size Exclusion Chromatography - High Performance Liquid Chromatography (SEC-HPLC)", "Gel Electrophoresis"],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": ["flatDoses"],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": ["nextStep"],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Physicochemical stability of 25 mg/mL pemetrexed diarginine in partially used vials and 3 and 12 mg/mL diluted in dextrose 5% in polyolefin bag",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A30.2",
    "authors": "YE Nisse, J Vigneron, N Sobalak, B Demoré",
    "institution": "Chru Nancy, Pharmacy, Vandoeuvre-Lès-Nancy, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.67",
    "filters": {
      "actSubs": ["Pemetrexed"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["High Performance Liquid Chromatography (HPLC)"],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Storage of nivolumab pembrolizumab and daratumumab for 14 days after compounding in the hospital pharmacy: a microbiological stability study",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A31.1",
    "authors": "L Cancanelli, F Selmin, L Camuffo, G Mangoni, M Piccoli, M Rivano, F Cilurzo, P Minghetti",
    "institution": "Università Degli Studi Di Milano, Department of Pharmaceutical Sciences, Milan, Italy",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.68",
    "filters": {
      "actSubs": ["Nivolumab", "Pembrolizumab", "Daratumumab"],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Italy"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Particulate quality of a controlled atmosphere area. Compliance with good manufacturing practices at rest and during activity, highlighting factors impacting on contamination",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A31.2",
    "authors": "M Pottier, M Naveau, A Villain, G Strobbe, I Sakji, F Feutry, G Marliot",
    "institution": "Centre Oscar Lambret, Pharmacy, Lille, France",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.69",
    "filters": {
      "actSubs": [],
      "indication": [],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["France"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": ["policiesAudits"],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Development and validation of a discriminative method for anthracyclines used in oncology by visible spectrometer",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A32.1",
    "authors": "CA Adade, A El Orche, H Attjioui, A Cheikh, H Mefetah, M El Karbane, M Bouatia",
    "institution": "Mohamed V University-Faculty of Medicine and Pharmacy, Analytical Chemistry Laboratory, Rabat, Morocco. University of Sultan Moulay Slimane Beni-Mellal, Faculty of Science and Technology, Beni-Mellal, Morocco. Abulcasis University of Health Sciences, Faculty of Pharmacy, Rabat, Morocco. Paediatric Hospital, Pharmacy, Rabat, Morocco",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.70",
    "filters": {
      "actSubs": ["Daunorubicin", "Doxorubicin", "Epirubicin"],
      "indication": [],
      "statedClass": ["Anthracyclines"],
      "typeOfMedical": [],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": ["Paediatric Haematology – Oncology"],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Partial Least Squares Discriminant Analysis (PLS-DA)", "Ultraviolet – Visible Spectrophotometry"],
      "studyLength": [],
      "country": ["Morocco"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": ["pediatrics"],
      "geriatrics": [],
      "neonatology": [],
      "oncology": ["oncology"],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": ["costAnalysis"],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "The effects of freeze–thaw cycling on the stability of the adalimumab biosimilar SB5",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A32.2",
    "authors": "H Ebbers, J Kim, J Yun, D Park, SJ Hwang, SJ Park",
    "institution": "Biogen International GmbH, Scientific Affairs, Baar, Switzerland. Samsung Bioepis Co Ltd, Qc Group, Incheon, Korea South",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.71",
    "filters": {
      "actSubs": ["Adalimumab"],
      "indication": [],
      "statedClass": ["Biosimilars"],
      "typeOfMedical": ["Prefilled Syringes"],
      "studyDesign": ["Test-Tube Lab Research"],
      "setting": ["Laboratory"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": ["Size Exclusion Chromatography - High Performance Liquid Chromatography (SEC-HPLC)", "Capillary Electrophoresis - Sodium Dodecyl Sulfate (CE-SDS) (non-reducing)", "Fluorescence Resonance Energy Transfer (FRET)"],
      "studyLength": [],
      "country": ["Switzerland", "South Korea"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": [],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": [],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": ["stability"],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": ["stock"],
      "automated": [],
      "coldChain": ["coldChain"],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": ["institutional"],
      "recalls": [],
      "education": [],
      "clinicalTrials": ["clinicalTrials"],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  },
  {
    "title": "Magistral formulation for a patient with multiple food allergy",
    "url": "https://ejhp.bmj.com/content/27/Suppl_1/A33.1",
    "authors": "Y Jiménez López, E Pérez Cano, M Merino Almazán, R Claramunt García, MI Sierra Torres, I Caba Porras",
    "institution": "Hospital Universitario De Jaén, Pharmacy Service, Jaén, Spain",
    "DOI": "http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.72",
    "filters": {
      "actSubs": ["Iron", "Zinc", "Sirolimus"],
      "indication": ["Multiple Food Allergy (MFA)"],
      "statedClass": [],
      "typeOfMedical": [],
      "studyDesign": [],
      "setting": ["Hospital"],
      "ward": [],
      "numPatients": [],
      "numPrescriptions": [],
      "criteriaMethod": [],
      "studyLength": [],
      "country": ["Spain"],
      "year": ["2020"],
      "journal": ["European Journal of Hospital Pharmacy (EJHP)"],
      "pediatrics": ["pediatrics"],
      "geriatrics": [],
      "neonatology": [],
      "oncology": [],
      "pharmacogenetics": [],
      "pharmacoeconomy": [],
      "radiopharmaceuticals": [],
      "compounding": ["compounding"],
      "medicalDevices": [],
      "personalized": [],
      "nutrition": [],
      "highRisk": [],
      "endOfLife": [],
      "selfMedication": [],
      "preopMedication": [],
      "outpatient": [],
      "enzymeSubstrate": [],
      "geneTherapy": [],
      "homeCare": [],
      "antibioticProphylaxis": [],
      "painManagement": [],
      "offLabel": [],
      "flatDoses": [],
      "switching": [],
      "deprescribing": [],
      "prepareIV": [],
      "costAnalysis": [],
      "riskSafety": [],
      "vigilance": [],
      "stability": [],
      "drugMonitoring": [],
      "safetyProfile": [],
      "intervention": [],
      "patientIntervention": [],
      "nursesReccomend": [],
      "telepharmacy": [],
      "interview": [],
      "selection": [],
      "stock": [],
      "automated": [],
      "coldChain": [],
      "softwareAided": [],
      "mobileVR": [],
      "Printing3D": [],
      "socialMedia": [],
      "shortages": [],
      "adverseEvents": [],
      "adherence": [],
      "resistance": [],
      "renal": [],
      "errors": [],
      "administrative": [],
      "stewardship": [],
      "policiesAudits": [],
      "multidisciplinary": [],
      "institutional": [],
      "recalls": [],
      "education": [],
      "clinicalTrials": [],
      "youngPharma": [],
      "nextStep": [],
      "compliance": [],
      "orphan": [],
      "delivery": [],
      "falsified": [],
      "incompatibilities": []
    }
  }
]